DadFinStart your free week
DadFin › Stocks › Healthcare › ADPT

Adaptive Biotechnologies Corporati (ADPT) stock score

Healthcare · Diagnostics & Research · United States

$26.49 ▲ +1.53% today

84.4
Dad Score, out of 100
good

Adaptive Biotechnologies Corporati (ADPT) is a Diagnostics & Research company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 84.4 out of 100 on the Dad Score, a good reading that places the business ahead of 84% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #136 of 974. Its strongest axes are growth, price action and conviction; its weakest is risk.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Average
Quality
Average
Growth
Strong
Price action
Above average
Risk
Weak
Conviction
Above average
Liquidity
Strong
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)0.0×
P/E (forward)-157.1×
Dividend yield0.00%
Return on capital-11.3%
Operating margin-22.0%
Revenue growth (YoY)+54.8%
FCF yield-1.1%
Net debt / EBITDA3.00×
Piotroski F-Score5 / 9
52-week change+95.9%
Market cap$4.5B
Next earningsNov 4, 2026

What subscribers see on ADPT

Start your free weekSubscriber? Open the full research →

Diagnostics & Research peers

StockCompanyDad ScoreBandMarket cap
TMOThermo Fisher Scientific Inc.77.0good$242.1B
DHRDanaher Corporation79.6good$150.5B
NTRANatera, Inc.86.1strong$59.1B
AAgilent Technologies, Inc.79.9good$47.3B
IQVIQVIA Holdings Inc.82.3good$42.5B
WATWaters Corporation78.8good$41.7B
ILMNIllumina, Inc.35.1weak$41.2B
IDXXIDEXX Laboratories, Inc.90.1strong$40.9B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.